Sonnet Biotherapeutics announced its proprietary Antibody Drug Conjugate (ADC) platform is ready for drug discovery partnerships, with the potential to produce multiple pipeline candidates, including a construct called SON-5010 that showed promising preclinical results compared to existing treatments.